Inventiva（6IV）株式概要臨床段階のバイオ医薬品会社であるInventiva S.A.は、代謝機能障害関連脂肪性肝炎（MASH）およびその他の疾患の治療のための経口低分子治療薬の開発に重点を置き、フランス国内および国際的に活動している。 詳細6IV ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長3/6過去の実績0/6財務の健全性1/6配当金0/6報酬収益は年間51.27%増加すると予測されています リスク分析株式の流動性は非常に低い マイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見る6IV Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€3.141.3k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-488m54m2016201920222025202620282031Revenue €53.6mEarnings €10.0mAdvancedSet Fair ValueView all narrativesInventiva S.A. 競合他社FormyconSymbol: XTRA:FYBMarket cap: €353.1mBiotest GmbH KGaASymbol: HMSE:BIO0Market cap: €1.3bBiotestSymbol: XTRA:BIO3Market cap: €1.4bDextech MedicalSymbol: DB:LQ0Market cap: €197.8m価格と性能株価の高値、安値、推移の概要Inventiva過去の株価現在の株価€3.1452週高値€6.1552週安値€3.14ベータ0.881ヶ月の変化-34.28%3ヶ月変化-40.51%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-48.54%最新ニュースお知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris Franceお知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026最新情報をもっと見るRecent updatesお知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris Franceお知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026お知らせ • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231お知らせ • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.お知らせ • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.お知らせ • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.株主還元6IVDE BiotechsDE 市場7D-26.2%-1.6%1.5%1Yn/a-5.1%3.3%株主還元を見る業界別リターン: 6IVがGerman Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 6IV German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 6IV's price volatile compared to industry and market?6IV volatility6IV Average Weekly Movementn/aBiotechs Industry Average Movement9.0%Market Average Movement5.9%10% most volatile stocks in DE Market13.1%10% least volatile stocks in DE Market2.8%安定した株価: 6IVの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の6IVのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201173Andrew Obenshaininventivapharma.comInventiva S.A.は臨床段階にあるバイオ医薬品会社で、代謝機能障害関連脂肪性肝炎（MASH）およびその他の疾患の治療を目的とした経口低分子治療薬の開発に重点を置き、フランス国内および国際的に活動している。新規の汎ペルオキシソーム増殖剤活性化受容体作動薬であるラニフィブラノール（MASH成人患者を対象としたNATiV3第3相臨床試験中）、およびムコ多糖症患者を対象としたオディパルシルを開発している。また、特発性肺線維症治療のための前臨床プログラムであるTGF-βの開発も行っている。同社は2011年に設立され、フランスのダイクスに本社を置いている。もっと見るInventiva S.A. 基礎のまとめInventiva の収益と売上を時価総額と比較するとどうか。6IV 基礎統計学時価総額€651.16m収益（TTM）-€354.14m売上高(TTM)€6.76m96.3xP/Sレシオ-1.8xPER（株価収益率6IV は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6IV 損益計算書（TTM）収益€6.76m売上原価€22.00k売上総利益€6.74mその他の費用€360.88m収益-€354.14m直近の収益報告Dec 31, 2025次回決算日Sep 25, 2026一株当たり利益（EPS）-1.70グロス・マージン99.67%純利益率-5,237.95%有利子負債／自己資本比率-799.8%6IV の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 05:46終値2026/06/16 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Inventiva S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Eliana MerleBarclaysEdward NashCanaccord GenuityEtzer DaroutGuggenheim Securities, LLC19 その他のアナリストを表示
お知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264
お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.
お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris France
お知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.
Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264
お知らせ • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.
お知らせ • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris France
お知らせ • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.
Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026
お知らせ • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231
お知らせ • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)
Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.
お知らせ • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
お知らせ • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.
Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.
Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.
